GlobeNewswire by notified

Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center

Share

Basel, Switzerland, April 27, 2022

Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with bacterial and fungal infections and cancer, announced today that it has entered into a licensing agreement with the U.S.-based company, Fox Chase Chemical Diversity Center, Inc. (FCCDC), for a preclinical program on novel first-in-class broad spectrum antifungals with activity against difficult-to-treat mold infections.

Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: “This agreement shows our commitment to implementing our new corporate strategy, with a future focus on anti-infectives. The profile and the broad antifungal activity of the lead compound shown in preclinical studies are very promising. We will now focus on completing the preclinical profiling of the lead compound, which will be decisive for the development strategy and positioning of this new class of antifungal agents.”

Under the terms of the agreement, Basilea is granted an exclusive worldwide license to FCCDC’s antifungal program. FCCDC receives an undisclosed upfront payment and is eligible for further payments, upon the achievement of predefined development, regulatory and commercial milestones, as well as for tiered royalties on net sales. This transaction has no impact on Basilea’s financial guidance for 2022, provided on February 15, 2022.

About FCCDC

Fox Chase Chemical Diversity Center, Inc. (FCCDC) is based in Doylestown, Pennsylvania, USA, at the Pennsylvania Biotechnology Center (PABC) and is affiliated with the Pennsylvania Drug Discovery Institute (PDDI). FCCDC conducts early-stage drug discovery research including target validation, medicinal chemistry, in vitro pharmacology, and ADME characterization. FCCDC’s goal is to transition innovative biomedical research technologies into fully-fledged development programs for eventual evaluation in human clinical trials and commercialization. The work on FCCDC’s antifungal program was supported by the U.S. Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award No. W81XWH-18-1-0638.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with bacterial and fungal infections and cancer. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have several preclinical assets in both anti-infectives and cancer in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

PRESS RELEASE: NQX has been certified by NCSA-FI for security level TL III24.5.2022 10:15:00 CEST | Press release

NQX has been certified by NCSA-FI for security level TL III SSH announced today that it has received a TL III-level security certification for its NQX quantum line encryption software version 2.2 from the Finnish National Cyber Security Center (NCSA). The certification enables the solution to be used to secure networks requiring TL III level encryption for the transmission of confidential and sensitive information. The certified NQX 2.2 includes central management functionality that enables convenient remote management of network nodes. NQX central manager simplifies and automates the management and maintenance of Public Key Infrastructures (PKI) and certifications of nodes and connections regardless of their location. Because of its intuitive user interface, NQX central manager is easy to use and administrators can perform critical management tasks with minimal human effort. NQX's capability to support various network deployment approaches is enhanced with an isolated management chann

Selligent Marketing Cloud Boosts Customer Engagement with New Smart Subject Capabilities24.5.2022 10:00:00 CEST | Press release

AI Drives Next-Generation Subject Line Optimization for Marketers, Saving Time and Increasing Performance BRUSSELS, Belgium and NASHVILLE, Tenn., May 24, 2022 (GLOBE NEWSWIRE) -- Selligent Marketing Cloud (Selligent), the intelligent omnichannel marketing automation platform and CM Group brand, today announced the launch of Smart Subject, an AI-based individual subject line optimization capability that improves campaign performance and reduces the manual labor of subject line creation for marketers. Smart Subject, along with a series of other new AI-capability offerings, is built to help brands stand out in a crowded inbox, enhancing personalized marketing across languages. With Smart Subject, marketers can send the optimal subject line for every contact in their segment through the use of: Automatic Subject Line Matching: Selligent’s Natural Language Processing-based engine will find the optimal subject line for every contact.Instant Feedback: Smart Subject can identify what percentag

Spryker App Composition Platform Accelerates Industry Transition Towards True Composable Commerce24.5.2022 10:00:00 CEST | Press release

New “App Store” enables revolutionary approach to composable commerce for enterprises that slashes integration time, radically reduces costs, and helps businesses to adapt and differentiate BERLIN and NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Spryker, the fastest-growing enterprise digital commerce platform for B2B, Enterprise Marketplaces, Unified Commerce and D2C, has released a new version of its App Composition Platform at Spryker EXCITE 2022. The cloud-native platform will give enterprises seamless access to third-party services and best-of-breed digital commerce vendors via an industry-first trial model which includes full service level agreement (SLA) and software lifecycle coverage for all composed capabilities. Spryker App Composition Platform will revolutionize how organizations integrate third-party services and other best-of-breed products into their business landscape and will deliver a true composable commerce experience so customers can benefit from access to new apps i

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES24.5.2022 09:30:00 CEST | Press release

Bid date, 2022-05-24Auction date2022-05-24Settlement date2022-05-25Maturity Date2022-06-01Nominal amount603 billion SEKInterest rate0.25 %Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume603 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term1205 billion SEKExpected excess liquidity at full allotment602 billion SEK Stockholm, 2022-05-24